Bayer is pressing ahead with a phase 3 trial of its oral Factor XIa inhibitor asundexian, a new anticoagulant, despite missing efficacy targets in two mid-stage studies. The OCEANIC trial ...

Bayer has added another phase 3 trial into its registration programme for oral Factor XIa inhibitor asundexian, signalling growing confidence in a drug that generated mixed results in phase 2.

Hosted by Dr. Negar Asdaghi, each episode of Stroke's monthly podcast, Stroke Alert, begins by posing key takeaway questions from featured articles in the current issue of Stroke. This is followed by ...